578 related articles for article (PubMed ID: 25762475)
1. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Nagaraj G; Ma C
Breast Cancer Res Treat; 2015 Apr; 150(2):231-42. PubMed ID: 25762475
[TBL] [Abstract][Full Text] [Related]
2. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
3. Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.
Kaklamani VG; Gradishar WJ
Oncologist; 2017 May; 22(5):507-517. PubMed ID: 28314835
[TBL] [Abstract][Full Text] [Related]
4. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
5. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
6. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S; Zelnak A; O'Regan R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
[TBL] [Abstract][Full Text] [Related]
7. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
9. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
10. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
Provenzano A; Kurian S; Abraham J
Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
[TBL] [Abstract][Full Text] [Related]
11. [New therapeutical strategies in metastatic hormone-dependent breast cancer].
Vilquin P; Cohen P; Maudelonde T; Tredan O; Treilleux I; Bachelot T; Heudel PE
Bull Cancer; 2015 Apr; 102(4):367-80. PubMed ID: 25799877
[TBL] [Abstract][Full Text] [Related]
12. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Dalmau E; Armengol-Alonso A; Muñoz M; Seguí-Palmer MÁ
Breast; 2014 Dec; 23(6):710-20. PubMed ID: 25311296
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies to overcome resistance to endocrine therapy for breast cancer.
Ziauddin MF; Hua D; Tang SC
Cancer Metastasis Rev; 2014 Sep; 33(2-3):791-807. PubMed ID: 24944077
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.
Mancuso MR; Massarweh SA
Curr Probl Cancer; 2016; 40(2-4):95-105. PubMed ID: 27839747
[TBL] [Abstract][Full Text] [Related]
15. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Brufsky AM; Dickler MN
Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
[TBL] [Abstract][Full Text] [Related]
16. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
17. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
[TBL] [Abstract][Full Text] [Related]
18. The changing role of ER in endocrine resistance.
Nardone A; De Angelis C; Trivedi MV; Osborne CK; Schiff R
Breast; 2015 Nov; 24 Suppl 2(0 2):S60-6. PubMed ID: 26271713
[TBL] [Abstract][Full Text] [Related]
19. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
20. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Nagaraj G; Ma CX
Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]